Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. 

The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

1988: The company was founded by Alfred G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8 and is headquartered in Tarrytown, NY.“ One of our best hopes for fighting the coronavirus pandemic may have started with a signed napkin.

1989: Yancopoulos had bailed on Columbia to join Schleifer as Regeneron's chief scientific officer, setting up shop in Tarrytown, New York, about 20 miles north of Manhattan.

1991: While many biotechs are secretive, Regeneron's researchers were encouraged to publish early and often, said Stahl, who joined in 

1991. Its early research helped the company gain some attention and raise a $91 million initial public offering.

2008: Approved by the FDA in February.

2010: Regeneron had more than 1,000 employees and a market value north of $1 billion.

2011: Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's New York Entrepreneur Of The Year®

2012: Zaltrap (aflibercept injection) for metastatic colorectal cancer approved by the FDA in August.

2013: The drug brought in $1.4 billion in US sales and has kept growing since then.

2014: Regeneron was also cofounded by Eric Shooter, a Stanford University neuroscientist who served on the biotech's board until that year.

2015: Approved by the FDA in July, it is reported to cost $4,500 to $8,000 per year.

2017: Approved by the FDA in March.

2018: Approved by the FDA in September.

2020: On February 4, the United States Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19. In October 2020 when United States President Donald Trump was infected with COVID-19 and taken to Walter Reed National Military Medical Center in Bethesda, Maryland, he was administered REGN-COV2. In the filing, it specified that it currently had 50,000 doses and that it expected to reach a total of 300,000 doses "within the next few months." The FDA granted approval for emergency use authorization in November. Antibody drugs could be a "bridge to a vaccine" by being ready by the end of the year. 

2021: Regeneron among the 100 Fastest-Growing Companies Great Place To Work: Fortune 100 Best Companies to Work For.

2022: Regeneron to Report Second Quarter Financial and Operating Results and Host Conference Call and Webcast on August 3.

According to Regeneron Pharmaceuticals, the company's mission is to use the power of science to bring new medicines to patients.

As mentioned on its website:

“We are intent on deepening our strong and sustainable portfolio of innovative medicines. We are improving the traditional drug development process through proprietary technologies that accelerate the time from discovery to drug approval and improve the likelihood of success. We are also leading ambitious initiatives, such as the Regeneron Genetics Center®, one of the largest genetics sequencing efforts in the world.” 

According to Regeneron Pharmaceuticals, the company vision is: “to become a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases".

“With inspiring scientific and patient collaborations and a legacy of cutting-edge, homegrown innovation, we are committed to improving the lives of people with serious diseases by discovering new treatments for unmet medical needs.”

Some of the marketed products of the company are:

• Arcalyst (rilonacept) is used for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.
• Eylea (aflibercept injection) was approved by the U.S. Food and Drug Administration (FDA) in November 2011 to treat a common cause of blindness in the elderly. Eylea is reported to cost $11,000 per year for each eye treated.
• Zaltrap (aflibercept injection) is used for metastatic colorectal cancer approved by the FDA in August 2012.
• Praluent (alirocumab) is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by the FDA in July 2015. It is reported to cost $4,500 to $8,000 per year.
• Dupixent (dupilumab injection) is for the treatment of adolescent and adult patients' atopic dermatitis. It was approved by the FDA in March 2017[28] and is reported to cost $37,000 per year.
• Kevzara (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment of adults with rheumatoid arthritis approved by the FDA in May 2017. Trials commenced in March 2020 to evaluate the effectiveness of Kevzara in the treatment of COVID-19.
• Libtayo (cemiplimab injection) is a monoclonal antibody targeting the PD-1 pathway as a checkpoint inhibitor, for the treatment of people with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Libtayo was approved by the FDA in September 2018.
• Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of three antibodies, developed to treat deadly Ebola virus. In October 2020, the U.S. Food and Drug Administration (FDA) approved it with an indication for the treatment of infection caused by Zaire ebolavirus.

Some of the other technology platforms of the company are:

Trap Fusion Proteins: Regeneron's novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.

Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.